



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 03-1-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 27-12-2008 TO BE PUBLISHED 05-1-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
**Karachi**

No.2/2/2003-F.Sec.

Dated: 03-1-2009

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 27-12-2008 TO BE PUBLISHED 05-1-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000


1512/2008	<b><u>22-12-2008</u></b> 1.Muhammad Rauf, 2.Muhammad Kamran, 3.Khalid Jamil, 4. Askari Begum and 5.Nida Saleem Karachi, Pakistan	“A process for the production of date powder from yellow dated (khalal stage)”
1513/2008	B. T. Innovation GmbH., Germany (Priority 21-12-07 Germany)	“A functional construction element and a method for producing the same”
1514/2008	Syngenta Participations AG, Switzerland (Priority 24-12-07 UK)	“Insecticidal compounds”
1515/2008	GlaxoSmithKline Biologicals S.A., Belgium (Priority 24-12-07 USA)	“Vaccines for malaria”
1516/2008	<b><u>23-12-2008</u></b> AstraZeneca AB, Sweden	“Morpholino pyrimidine derivatives used in diseases linked to motor kinase and/or P13K”
1517/2008	Shell Internationale Research Maatschappij B.V., Netherlands (Priority 28-12-07 EPC)	“New uses”
1518/2008	<b><u>24-12-2008</u></b> Nokia Siemens Networks OY, Finland (Priority 31-12-07 Europe)	“Enhanced presence server system”
1519/2008	Bayer Schering Pharma Aktiengesellschaft, Germany (Priority 29-12-07 German)	“17-hydroxy-19-nor-21-carboxylic acid-steroid $\delta$ -lactone derivative, use thereof and medicinal products containing the derivatives”
1520/2008	Bayer Schering Pharma Aktiengesellschaft, Germany, (Priority 29-12-07 Germany)	“17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative, use thereof and medicinal products containing the derivative”

1521/2008	Bayer Schering Pharma Aktiengesellschaft, Germany, (Priority 29-12-07 Germany)	“15, 16-methylene 17-hydroxy-19-nor-21-carboxylic acid-steroid $\gamma$ -lactone derivative, use thereof and medicinal products containing the derivative”
1522/2008	Bayer Schering Pharma Aktiengesellschaft, Germany, (Priority 29-12-07 Germany)	“15, 16-methylene -17-(1-propenyl)-17-3-oxidoestra-4-en-3- derivative, use thereof and drug containing the derivative”
1523/2008	Bayer Schering Pharma Aktiengesellschaft, Germany, (Priority 29-12-07 Germany)	“19-Nor – steroid derivatives with a 15 a, 16 a-methylene group and a saturated 17, 17-spirolactone ring, use thereof and medicinal products containing these derivatives”
1524/2008	Eisai R&D management Co., Ltd. Japan (Priority 27-12-07 Japan)	“Heterocyclic ring and phosphoxymethyl group substituted pyridine derivatives, and antifungal agents containing same ”
1525/2008	Sanofi –Aventis France (Priority 26-12-07 Europe)	“Process for the preparation of – substituted-1-(2H)-isoquinolones”
1526/2008	Calera Corporation, USA (Priority 28-12-07 USA)	“Method of sequestering CO <sub>2</sub> ”
	<b><u>26-12-2008</u></b>	
1527/2008	Mr. Pervez Akhter United Kingdom	“Improved jet engine”
1528/2008	1.ENI S.P.A., Italy 2.Institut Francais DU Petrole, France (Priority 04-1-08 Italy)	“Process for stabilizing the performance of a catalyst for fischer tropesch reaction
1529/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 27-12-07 Japan)	“Enzyme associated with equol synthesis”



**139900**

The invention relates to novel crystalline form of the compound 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene of the



and their use in pharmaceutical composition.

- 631/1998 SmithKline Beecham p.l.c., United Kingdom “Combination comprising 5-[4-]2-(N-methyl-N-(2-pyridyl) amino)ethoxy] benzyl]thiazolidine-2,4-dione and metformin”

(A61K, 31/44)

**139901**

A combination comprising from 2 to 8 mg of 5-[4-]2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione (compound (I) in a pharmaceutically acceptable form and upto 3000 mg of metformin in a pharmaceutically acceptable form, and a pharmaceutical composition comprising the same, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.

- 147/2000 SmithKline Beecham p.l.c., United Kingdom “A combination of a thiazolidinedione maleate and a biguanide antihyperglycaemic agent

(A61K, 31/155, A61K, 37/26)

**139902**

A combination comprising from 2 to 12 mg of the maleate salt of 5-[4[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] thiazolidine-2,4-dione (compound (I) and a biguanide antihyperglycaemic agent, and a pharmaceutical composition comprising the same, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.

259/2000 Otsuka  
Pharmaceutical Co.  
Limited,  
Japan “A composition comprising a fine powder of  
cilostazol”  
(A61K, 9/14)

**139903**

Provided is a cilostazol composition which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

737/2000 SmithKline Beecham  
Biological S.a.,  
Belgium “A vaccine comprising retrovirus variants and live  
attenuated retrovirus”  
(A61K, 39/15)

**139904**

The invention provides an attenuated rotavirus population comprising single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

84/2004 Boehringer Ingelheim  
International GmbH.,  
Germany “A pharmaceutical composition comprising a  
combination of dipyridamole, acetyl salicylic acid  
and an angiotensin II antagonist for stroke  
prevention”

(A61K, 31/60)


**139905**

A pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist that provides a stroke preventing effect superior to conventional medications or treatment regimes and useful in preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke.

456/2004 Glaxo Group Limited, “Substituted diketopiperazine compound”  
 United Kingdom  
 (A61K, 31/495)

139906

Compound of formula (I)




Wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino, pharmaceutical composition containing them and their use in medicine.

860/2004 Otsuka  
 Pharmaceutical Co.  
 Limited “2,3-dihydro-6-nitroimidazo[2,1-b]oxazole  
 compound”  
 (CO7D, 498/04)

139907

The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula:



in the above formula (1),  $R^1$  represents a hydrogen atom or C1-C6 alkyl group,  $n$  represents an integer of 0 to 6,  $R^1$  and  $-(CH_2)_nR^2$  may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring),



and  $R^2$  represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.

694/2005 Starlinger & Co.  
Gesellschaft m.b.H,  
Austria


“Veritable storage bag and process for its production”

(B65D, 33/01)

**139908**

A veritable bag, consisting of a flat web (1) of a bag material, which web is formed into a tube by overlapping their two opposing longitudinal edge regions, one end of the tube being sealed or configured as a bottom, respectively, with the bag material being essentially air-impermeable while exhibiting perforation holes (1g, 1h) in partial areas (1d, 1e; 1i, 1j; 1k, 1l, 1m, 1n; 1o, 1p, 1r, 1s) of each of the overlapping longitudinal edge regions. The perforation holes (1h) in one longitudinal edge region (1e) are offset with respect to the perforation holes (1g) in the other overlapped longitudinal edge region (1d), wherein the perforation holes (1g) in the overlapped longitudinal edge region (1d) exhibit a formation and/or an arrangement for an air permeability of at most the same but preferably a smaller extent than that of the perforation holes (1h) in the overlapping longitudinal edge region (1e).

Furthermore, the longitudinal edges (1a, 1b) of the overlapped longitudinal edge regions of the bag material web are fastened to the respective adjacent and overlapping layer of bag material (1) by means of a joint (2, 3). The bags according to the invention require less bag material than known bags and can be manufactured quickly and in an automated fashion in a small number of processing steps.



138/2006 Shell Internationale  
Research  
Maatschappij B.V.,  
Netherlands

“Method for removing contaminating gaseous components from a natural gas stream”

(BO1D, 53/24, CO7C, 7/09)

**139909**

A method for removing contaminating gaseous components, such as CO<sub>2</sub> and/or H<sub>2</sub>S, from a contaminated

natural gas stream, the method comprising:

- expanding the contaminated gas stream in an expander (1) thereby forming a contaminants enriched liquid phase and a contaminants depleted gaseous phase;
- allowing at least part of the contaminants in the expanded gas stream to liquify to form a dispersion of a contaminants enriched liquid phase in a contaminants depleted gaseous phase; and
- separating at least part of the contaminants enriched liquid phase from the contaminants

depleted gaseous phase in one or more centrifugal separators (2,3), which each comprise a bundle of parallel channels (19A) that are arranged within a spinning tube (4,5) parallel to an axis of rotation (7) of the spinning tube(s) (4,5).

642/2006 Tetra Laval Holdings & Finance S.A., Pully “Device and method for use in producing packages” (B65B, 9/20)

**139910**

A device (14) and a method for holding a portion (62) of a tube (40) of packaging material during sealing for obtaining an upper transverse seal (64) of the tube, the portion being arranged between the upper transverse seal and a lower transverse seal (66) of the tube, are provided. The device is arranged to control a cross section of a first part (62a) of the portion, by being in direct contact with it, so as to have a first tube extension (72) in a first direction (x) essentially perpendicular to a longitudinal direction (67) of the tube. The device is characterized in that it further is arranged to control a cross section of a second part (62b) of the portion, by being in direct contact with it, so as to have a second tube extension (74) in the first direction, the first part being arranged between the lower transverse seal of the tube and the second part of the portion, the second part being arranged between the upper transverse seal of the tube and the first part of the portion, and the first tube extension being larger than the second tube extension.

927/2006 Eton Systems AB, Sweden “Construction element for a device for forward feeding of a product carrier and a device comprising such a construction element”

(B65G, 17/20)

**139911**

Construction element for a device for forward feeding of product carriers (16), which construction element comprises a first beam section (14) presenting a main rail (15) intended to carry product carriers (16) movably resting on said main rail (15), a second beam section presenting a console

intended to carry an endless belt (1) or chain, which is intended to contribute to the forward feeding of said product carrier (16), and guiding means (19) running along said main rail (15) intended to retain product carriers (16) on the main rail (15), and also a device for forward feeding of product carriers including such a construction element.


1225/2006 Otsuka  
Pharmaceutical Co.,  
Limited,  
Japan

“A pharmacologically acceptable salt of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound”

(CO7D, 498/04)

### 139912

The present invention provides a 2, 3-dihydro-6-nitroimidazo [2,1-b] oxazole compound represented by the following general formula:



in the above formula (1), R<sup>1</sup> represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, (R)<sup>1</sup> and - (CH<sub>2</sub>)<sub>n</sub>R<sub>2</sub> may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring),



and R<sup>2</sup> represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.


1326/2006 Merck & Co., Inc.,  
USA

“A substituted acyl indole containing compound”

(CO7D, 209/08, CO7D, 401/04, CO7D, 403/04, CO7D, 417/04, A61K, 31/404, A61P, 3/00)

139913

The present invention relates to substituted indole of the formula I



The compound are glucagons receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus and related conditions.

1549/2006 Dr. Mansoor ahmad,  
National of Pakistan,  
Department of  
Pharmacognosy,  
University of Karachi

“A process for preparation of novel herbal composition containing cyperus rotundus”

(A61K, 31)

139914

This invention discloses a novel product invention of natural type where the ethereal extract of an indigenous medicinal herb cyperus rotundus material has been used as therapeutic agent against gastrointestinal tract (GIT) ulcer or any other infection. The plant extract has proved efficacy against animals and humans GIT ulcer or any other stomach infection.

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139567	Boehringer Ingelheim Pharmaceuticals, Inc., USA	870/1998
139568	Janssen Pharmaceutica NV. Belgium	545/2000
139569	F. Hoffmann-La Roche AG. Switzerland	522/2002
139570	Pfizer Products Inc., USA	910/2002
139571	Altana Pharma AG. Germany	360/2005
139572	F. Hoffmann-La Roche AG. Switzerland	449/2005
139573	ENI S.P.A. and Enitecnologie S.P.A., Italy.	1137/2005
139574	Pfizer Products Inc., USA	177/2007

**(MRS. YASMEEN ABBASI)**  
**CONTROLLER OF PATENTS**  
Tel: 9215488